The thalamus and multiple sclerosis: Modern views on pathologic, imaging, and clinical aspects

Neurology

Volumn 80, Issue 2, 2013, Pages 210-219

  Minagar, Alireza ^a   Barnett, Michael H ^b,c   Benedict, Ralph H B ^d   Pelletier, Daniel ^f   Pirko, Istvan ^g   Sahraian, Mohamad Ali ^h   Frohman, Elliott ⁱ   Zivadinov, Robert ^d,e  

^a Louisiana State University School of Medicine Shreveport   (United States)

^b ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

^d JACOBS NEUROLOGICAL INSTITUTE   (United States)

^e UNIVERSITY AT BUFFALO   (United States)

^f YALE UNIVERSITY   (United States)

^g MAYO CLINIC   (United States)

^h TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

ⁱ UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; IRON;

BRAIN CORTEX ATROPHY; BRAIN CORTEX LESION; CLINICAL FEATURE; CLINICALLY ISOLATED INFLAMMATORY DEMYELINATING SYNDROME; COGNITIVE DEFECT; DEMYELINATING DISEASE; DIFFUSE AXONAL INJURY; DIFFUSION TENSOR IMAGING; DIFFUSION WEIGHTED IMAGING; DISEASE ASSOCIATION; FATIGUE; GRAY MATTER; HISTOPATHOLOGY; HUMAN; HYPOTHALAMUS LESION; INFLAMMATION; MOTOR DYSFUNCTION; MULTIPLE SCLEROSIS; NEUROIMAGING; NEUROPATHOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; OLIGODENDROGLIA; PAROXYSMAL DYSTONIA; PRIORITY JOURNAL; REVIEW; SUSCEPTIBILITY WEIGHTED IMAGING; THALAMUS; WHITE MATTER LESION;

HUMANS; MULTIPLE SCLEROSIS; NEUROIMAGING; NEUROLOGIC EXAMINATION; NEURONS; THALAMUS;

EID: 84873636164     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e31827b910b     Document Type: Review

References (60)

1. Kutzelnigg A, Lassmann H. Cortical lesions and brain atrophy in MS. J Neurol Sci 2005;233:55-59. (Pubitemid 40804816)
2. Wegner C, Esiri MM, Chance SA, Palace J, Matthews PM. Neocortical neuronal, synaptic, and glial loss in multiple sclerosis. Neurology 2006;67:960-967. (Pubitemid 44454585)
3. Lucchinetti CF, Popescu BF, Bunyan RF, et al. Inflammatory cortical demyelination in early multiple sclerosis. N Engl J Med 2011;365:2188-2197.
4. Dutta R, Chang A, Doud MK, et al. Demyelination causes synaptic alterations in hippocampi from multiple sclerosis patients. Ann Neurol 2011;69:445-454.
5. Popescu BF, Lucchinetti CF. Meningeal and cortical grey matter pathology in multiple sclerosis. BMC Neurol 2012; 12:11.
6. Hulst HE, Geurts JJ. Gray matter imaging in multiple sclerosis: what have we learned? BMC Neurol 2011;11:153.
7. Cifelli A, Arridge M, Jezzard P, Esiri MM, Palace J, Matthews PM. Thalamic neurodegeneration in multiple sclerosis. Ann Neurol 2002;52:650-653. (Pubitemid 35246871)
8. Vercellino M, Masera S, Lorenzatti M, et al. Demyelina-tion, inflammation, and neurodegeneration in multiple sclerosis deep gray matter. J Neuropathol Exp Neurol 2009;68:489-502.
9. Vercellino M, Plano F, Votta B, Mutani R, Giordana MT, Cavalla P. Grey matter pathology in multiple sclerosis. J Neuropathol Exp Neurol 2005;64:1101-1107.
10. Gilmore CP, Donaldson I, Bo L, Owens T, Lowe J, Evangelou N. Regional variations in the extent and pattern of grey matter demyelination in multiple sclerosis: a comparison between the cerebral cortex, cerebellar cortex, deep grey matter nuclei and the spinal cord. J Neurol Neurosurg Psychiatry 2009;80:182-187.
11. Henry RG, Shieh M, Amirbekian B, Chung S, Okuda DT, Pelletier D. Connecting white matter injury and thalamic atrophy in clinically isolated syndromes. J Neurol Sci 2009;282:61-66.
12. Henry RG, Shieh M, Okuda DT, Evangelista A, Gornoini ML, Pelletier D. Regional grey matter atrophy in clinically isolated syndromes at presentation. J Neurol Neurosurg Psychiatry 2008;79:1236-1244.
13. Ramasamy DP, Benedict R, Cox JL, et al. Extent of cerebellum, subcortical and cortical atrophy in patients with MS: a case-control study. J Neurol Sci 2009;282:47-54.
14. Calabrese M, Rinaldi F, Mattisi I, et al. The predictive value of gray matter atrophy in clinically isolated syndromes. Neurology 2011;77:257-263.
15. Rocca MA, Mesaros S, Pagani E, Sormani MP, Comi G, Filippi M. Thalamic damage and long-term progression of disability in multiple sclerosis. Radiology 2010;257:463-469.
16. Houtchens MK, Benedict RH, Killiany R, et al. Thalamic atrophy and cognition in multiple sclerosis. Neurology 2007;69:1213-1223. (Pubitemid 47429021)
17. Sullivan EV, Rosenbloom M, Serventi KL, Pfefferbaum A. Effects of age and sex on volumes of the thalamus, pons, and cortex. Neurobiol Aging 2004;25:185-192. (Pubitemid 38124496)
18. Van Der Werf YD, Tisserand DJ, Visser PJ, et al. Tha-lamic volume predicts performance on tests of cognitive speed and decreases in healthy aging: a magnetic resonance imaging-based volumetric analysis. Brain Res Cogn Brain Res 2001;11:377-385. (Pubitemid 32406293)
19. Peterson JW, Bo L, Mork S, Chang A, Trapp BD. Transected neurites, apoptotic neurons, and reduced inflammation in cortical multiple sclerosis lesions. Ann Neurol 2001;50:389-400. (Pubitemid 32848742)
20. Magliozzi R, Columba-Cabezas S, Serafini B, Aloisi F. Intra-cerebral expression of CXCL13 and BAFF is accompanied by formation of lymphoid follicle-like structures in the meninges of mice with relapsing experimental autoimmune encephalomyelitis. J Neuroimmunol 2004;148:11-23. (Pubitemid 38229554)
21. Magliozzi R, Howell O, Vora A, et al. Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology. Brain 2007;130:1089-1104. (Pubitemid 47355604)
22. Brink BP, Veerhuis R, Breij EC, van der Valk P, Dijkstra CD, Bo L. The pathology of multiple sclerosis is location-dependent: no significant complement activation is detected in purely cortical lesions. J Neuropathol Exp Neurol 2005;64:147-155. (Pubitemid 40349313)
23. Bo L, Vedeler CA, Nyland HI, Trapp BD, Mork SJ. Sub-pial demyelination in the cerebral cortex of multiple sclerosis patients. J Neuropathol Exp Neurol 2003;62:723-732. (Pubitemid 36870458)
24. van Landeghem FK, Weiss T, von Deimling A. Expression of PACAP and glutamate transporter proteins in satellite oligodendrocytes of the human CNS. Regul Pept 2007;142:52-59. (Pubitemid 46766609)
25. Evangelou N, Konz D, Esiri MM, Smith S, Palace J, Matthews PM. Size-selective neuronal changes in the anterior optic pathways suggest a differential susceptibility to injury in multiple sclerosis. Brain 2001;124:1813-1820. (Pubitemid 32845442)
26. Pirko I, Lucchinetti CF, Sriram S, Bakshi R. Gray matter involvement in multiple sclerosis. Neurology 2007;68:634-642. (Pubitemid 46667808)
27. Poloni G, Minagar A, Haacke EM, Zivadinov R. Recent developments in imaging of multiple sclerosis. Neurologist 2011;17:185-204.
28. Calabrese M, Rinaldi F, Poretto V, Gallo P. The puzzle of multiple sclerosis: gray matter finds its place. Expert Rev Neurother 2011;11:1565-1568.
29. Seewann A, Kooi EJ, Roosendaal SD, et al. Postmortem verification of MS cortical lesion detection with 3D DIR. Neurology 2012;78:302-308.
30. Geurts JJ, Roosendaal SD, Calabrese M, et al. Consensus recommendations for MS cortical lesion scoring using double inversion recovery MRI. Neurology 2011;76: 418-424.
31. Calabrese M, Atzori M, Bernardi V, et al. Cortical atrophy is relevant in multiple sclerosis at clinical onset. J Neurol 2007;254:1212-1220. (Pubitemid 350112349)
32. Fisniku LK, Altmann DR, Cercignani M, et al. Magnetization transfer ratio abnormalities reflect clinically relevantgrey matter damage in multiple sclerosis. Mult Scler 2009; 15:668-677.
33. Audoin B, Zaaraoui W, Reuter F, et al. Atrophy mainly affects the limbic system and the deep grey matter at the first stage of multiple sclerosis. J Neurol Neurosurg Psychiatry 2010;81:690-695.
34. Dalton CM, Chard DT, Davies GR, et al. Early development of multiple sclerosis is associated with progressive grey matter atrophy in patients presenting with clinically isolated syndromes. Brain 2004;127:1101-1107. (Pubitemid 38623045)
35. Ceccarelli A, Rocca MA, Pagani E, et al. A voxel-based morphometry study of grey matter loss in MS patients with different clinical phenotypes. Neuroimage 2008;42:315-322.
36. Calabrese M, Rinaldi F, Grossi P, et al. Basal ganglia and frontal/parietal cortical atrophy is associated with fatigue in relapsing-remitting multiple sclerosis. Mult Scler 2010;16:1220-1228.
37. Mesaros S, Rocca MA, Absinta M, et al. Evidence of tha-lamic gray matter loss in pediatric multiple sclerosis. Neurology 2008;70:1107-1112. (Pubitemid 351464767)
38. Aubert-Broche B, Fonov V, Ghassemi R, et al. Regional brain atrophy in children with multiple sclerosis. Neuro-image 2011;58:409-415.
39. Kerbrat A, Aubert-Broche B, Fonov V, et al. Reduced head and brain size for age and disproportionately smaller thal-ami in child-onset MS. Neurology 2012;78:194-201.
40. Till C, Ghassemi R, Aubert-Broche B, et al. MRI correlates of cognitive impairment in childhood-onset multiple sclerosis. Neuropsychology 2011;25:319-332.
41. Hagemeier J, Weinstock-Guttman B, Bergsland N, et al. Iron deposition on SWI-filtered phase in the subcortical deep gray matter of patients with clinically isolated syndrome may precede structure-specific atrophy. AJNR Am J Neuroradiol 2012;33:1596-1601.
42. Bakshi R, Benedict RH, Bermel RA, et al. T2 hypointen-sity in the deep gray matter of patients with multiple sclerosis: a quantitative magnetic resonance imaging study. Arch Neurol 2002;59:62-68. (Pubitemid 34052557)
43. Ceccarelli A, Filippi M, Neema M, et al. T2 hypointensity in the deep gray matter of patients with benign multiple sclerosis. Mult Scler 2009;15:678-686.
44. Zivadinov R, Heininen-Brown M, Schirda CV, et al. Abnormal subcortical deep-gray matter susceptibility-weighted imaging filtered phase measurements in patients with multiple sclerosis: a case-control study. Neuroimage 2012;59:331-339.
45. Khalil M, Enzinger C, Langkammer C, et al. Quantitative assessment of brain iron by R(2)&z.ast; relaxometry in patients with clinically isolated syndrome and relapsing-remitting multiple sclerosis. Mult Scler 2009;15:1048-1054.
46. Reich DS, Smith SA, Gordon-Lipkin EM, et al. Damage to the optic radiation in multiple sclerosis is associated with retinal injury and visual disability. Arch Neurol 2009;66:998-1006.
47. Davies GR, Ramio-Torrenta L, Hadjiprocopis A, et al. Evidence for grey matter MTR abnormality in minimally disabled patients with early relapsing-remitting multiple sclerosis. J Neurol Neurosurg Psychiatry 2004;75:998-1002. (Pubitemid 38869614)
48. Mesaros S, Rocca MA, Pagani E, et al. Thalamic damage predicts the evolution of primary-progressive multiple sclerosis at 5 years. AJNR Am J Neuroradiol 2011;32:1016-1020.
49. Tovar-Moll F, Evangelou IE, Chiu AW, et al. Thalamic involvement and its impact on clinical disability in patients with multiple sclerosis: a diffusion tensor imaging study at 3T. AJNR Am J Neuroradiol 2009;30:1380-1386.
50. Inglese M, Liu S, Babb JS, Mannon LJ, Grossman RI, Gonen O. Three-dimensional proton spectroscopy of deep gray matter nuclei in relapsing-remitting MS. Neurology 2004;63:170-172. (Pubitemid 38943801)
51. Wylezinska M, Cifelli A, Jezzard P, Palace J, Alecci M, Matthews PM. Thalamic neurodegeneration in relapsing-remitting multiple sclerosis. Neurology 2003;60:1949-1954. (Pubitemid 36736011)
52. Tellez N, Rio J, Tintore M, Nos C, Galan I, Montalban X. Fatigue in multiple sclerosis persists over time: a longitudinal study. J Neurol 2006;253:1466-1470.
53. Tartaglia MC, Narayanan S, Francis SJ, et al. The relationship between diffuse axonal damage and fatigue in multiple sclerosis. Arch Neurol 2004;61:201-207. (Pubitemid 38197551)
54. Leocani L, Colombo B, Comi G. Physiopathology of fatigue in multiple sclerosis. Neurol Sci 2008;29(suppl 2):S241-S243.
55. Minagar A, Sheremata WA, Weiner WJ. Transient movement disorders and multiple sclerosis. Parkinsonism Relat Disord 2002;9:111-113. (Pubitemid 35447537)
56. Zenzola A, De Mari M, De Blasi R, Carella A, Lamberti P. Paroxysmal dystonia with thalamic lesion in multiple sclerosis. Neurol Sci 2001;22:391-394. (Pubitemid 33771605)
57. Benedict RH, Weinstock-Guttman B, Fishman I, Sharma J, Tjoa CW, Bakshi R. Prediction of neuropsychological impairment in multiple sclerosis: comparison of conventional magnetic resonance imaging measures of atrophy and lesion burden. Arch Neurol 2004;61:226-230. (Pubitemid 38197556)
58. Benedict RH, Fischer JS, Archibald CJ, et al. Minimal neuropsychological assessment of MS patients: a consensus approach. Clin Neuropsychol 2002;16:381-397. (Pubitemid 36390381)
59. Batista S, Zivadinov R, Hoogs M, et al. Basal ganglia, thalamus and neocortical atrophy predicting slowed cognitive processing in multiple sclerosis. J Neurol 2012;259: 139-146.
60. Mesaros S, Rocca MA, Sormani MP, Charil A, Comi G, Filippi M. Clinical and conventional MRI predictors of disability and brain atrophy accumulation in RRMS: a large scale, short-term follow-up study. J Neurol 2008; 255:1378-1383.